Author, year, publication type and country | Patient’s characteristics | Treatments | Analysis type/model | Perspective/time horizon | Cost | Outcomes | |
---|---|---|---|---|---|---|---|
Comparators | Microspheres | ||||||
TARE versus TACE | |||||||
Rostambeigi, 2014 [20] Original article USA | BCLC-A BCLC-B BCLC-C | TARE versus TACE | TheraSphere™ SIR-Spheres® | CEA/Monte Carlo | Payer/5 years | Direct cost (medical) | OS and incremental cost |
Rostambeigi, 2014 [21] Communication at congress USA | BCLC-A BCLC-B BCLC-C | TARE versus TACE | ND | CEA/Monte Carlo | Payer/5 years | ND | OS, procedure- and complications costs, and incremental cost |
Manas, 2021 [22] Original article United Kingdom | BCLC-A BCLC-B | TARE versus TACE, TAE o DEB-TACE | TheraSphere™ | CUA/Markov | Payer/20 years | Direct cost (medical) | Downstaginga, LYG, QALY, ICER(£/LYG) y ICUR(£/QALY) |
Rognoni, 2018 [23] Original article Italy | BCLC-B | TTS: TARE + TACE + sorafenib (on 47% of patients) TS: TARE + sorafenib | TheraSphere™ SIR-Spheres® | CUA/Markov | Payer/lifetime | Direct cost (medical) | Cost, QALY, ICUR (€/QALY), WTP a €50,000/QALY |
TARE versus TKIs | |||||||
Chaplin, 2015 [24] Communication at congress United Kingdom | BCLC-Cb | TARE versus sorafenib | TheraSphere™ | CUA/Markov | Payer/10 years | ND | Cost, TTP, SG y ICUR (£/QALY), |
Palmer, 2017 [25] Communication at congress United Kingdom | BCLC-C | TARE versus sorafenib | SIR-Spheres® | Cost-minimization analysis | Payer/ND | Direct cost (medical) | Cost (£), principals factors cost, QALY |
Rognoni, 2017 [26] Original article Italy | BCLC-B BCLC-C | TARE versus sorafenib | ND | CUA/Markov | Payer/lifetime | Direct cost (medical) | Cost, QALY, ICUR (€/QALY), WTP a €38,500 (~ £30,000)/QALY |
Parikh, 2018 [27] Communication at congress USA | BCLC-Cc | TARE versus sorafenib | ND | CUA/Markov | Payer/lifetime | Direct cost (medical) | ICUR ($/QALY) |
Walton, 2020 [28] Systematic review an economic evaluation United Kingdom | BCLC-B BCLC-C (Child–Pugh A e ineligible a CTT) | TARE versus TKIs | TheraSphere™ SIR-Spheres® QuiremSpheres® | CUA/Partitioned survival model and decision tree | Payer and social/10 years | Direct and indirect cost | ICUR (£/QALY), incremental net monetary (NMB) |
Muszbek, 2020–21 [29] Original article United Kingdom | BCLC-Bd BCLC-Cd | TARE versus sorafenib | SIR-Spheres® | CUA/Partitioned survival model | Payer/lifetime | Direct cost (medical) | Cost, LYG, QALY, ICUR (£/QALY), WTP a £20.000, INB |
Marqueen, 2021 [30] Original article USA | BCLC-C | TARE versus sorafenib | TheraSphere™ SIR-Spheres® | CUA/Markov | Payer/5 years | Direct cost (medical) | Cost, QALY, ICUR (€/QALY), WTP a $100,000/QALY o $200,000/QALY |